Medcara, LLC.

WartPeel Patents

Patent No. 7,655,668 (“the ‘668 patent) 

This was the first issued patent and covers WartPEEL-type compositions.  The main claim reads as follows:

  1. A composition for treatment of warts consisting of: from 0.5 to 5.0% by weight 5-fluorouracil (5-FU); from 10.0 to 25.0% by weight salicylic acid; from 5 to 50% by weight of DMSO; from 1-10% by weight of a water-swellable polymer; and from 10-75% by weight of an adhesive; whereby the composition is a sustained release topical gel that releases salicylic acid onto the wart for removal of keratin of the wart and surrounding skin to allow penetration of the 5-FU into the wart.

 

Patent No. 8,236,814 

This patent issued from a divisional application of the ‘668 patent, and is directed to the method of treating warts using WartPEEL-type compositions.  The primary claim reads as follows:

  1. A method of treating warts comprising:  topically applying to a wart a therapeutically effective amount of a composition consisting essentially of from about 2-5% by weight 5-fluorouracil (5-FU), from about 10-25% by weight salicylic acid, from about 5-50% by weight organic solvent, said organic solvent being first combined with the 5-FU so as to dissolve the 5-FU followed by addition of salicylic acid followed by other ingredients of the composition; from about 1-10% by weight water-swellable polymer and an adhesive; and allowing the composition to release salicylic acid onto the wart to remove keratin from the wart and surrounding skin to allow penetration of the 5-FU into the wart.

 

Patent No. 8,367,683 

This patent is based on a continuation application filed from the ‘668 patent, and is also directed to WartPEEL-like compositions.  The broadest claim reads as follows:

  1. A composition for treatment of warts comprising:  from 0.5 to 5.0% by weight 5-fluorouracil (5-FU); from 10.0 to 25.0% by weight salicylic acid; from 5 to 50% by weight of organic solvent; from 1 to 10% by weight of a water-swellable polymer; and from 10-75% by weight of an adhesive; whereby the composition is a sustained release topical gel, said composition being acidic.
© 2021 Medcara, LLC. All Rights Reserved.